The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7 mg dexamethasone implant in patients with diabetic macular edema

PURPOSE: There are little or no published data comparing the outcomes of ILUVIEN(®) (0.19 mg fluocinolone acetonide [FAc]) and OZURDEX(®) (0.7 mg dexamethasone [DEX]) implants in patients with diabetic macular edema (DME), and this case sought to compare their outcomes. METHODS: This case was extrac...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, P, Chedid, A, Deuchler, SK, Kohnen, T, Müller, M, Koch, FH
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198890/
https://www.ncbi.nlm.nih.gov/pubmed/30410411
http://dx.doi.org/10.2147/IMCRJ.S174461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198890/
https://www.ncbi.nlm.nih.gov/pubmed/30410411
http://dx.doi.org/10.2147/IMCRJ.S174461

Ejemplares similares